|Day's Range||117.69 - 121.50|
|52 Week Range||87.50 - 139.79|
|PE Ratio (TTM)||-798.49|
|Earnings Date||Aug 2, 2017 - Aug 7, 2017|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||132.50|
Ligand Pharmaceuticals Incorporated (LGND) announced receipt of a milestone payment of $1.5 million after its partner Melinta Therapeutics' pipeline candidate Baxdela (delafloxacin) was approved by the FDA.
Ligand Pharmaceuticals Incorporated announces that partner Melinta Therapeutics, a privately held company focused on discovering, developing, and commercializing novel antibiotics to treat serious bacterial infections, announced yesterday that the U.S.
Ligand Pharmaceuticals (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.